ExThera and Asahi Kasei Medical secure exclusive distribution agreement in Japan
MARTINEZ, Calif., December 21, 2021--(BUSINESS WIRE)--ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera's Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). Per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval of Seraph 100 for commercialization in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005589/en/
"The agreement with ExThera Medical is of great significance for the further expansion in the intensive care business field, positioned as one of our growth drivers," said Shugo Sumiyoshi, President of Asahi Kasei Medical. "We believe the Seraph 100, with its unique adsorption capability, will add new value to our healthcare solutions and contribute to more lives saved."
The Seraph 100 adsorber is the first blood purification device capable of removing a wide range of pathogens from the blood and has been used with more than 800 USA and European Union patients, in over 70 hospitals. It has demonstrated reduced mortality and ICU length of stay in severe/critically ill COVID-19 patients in preliminary clinical studies1,2. The device received European CE mark in 2019 for the treatment of bloodstream infections, and was granted use in 2020 for use in critically ill COVID-19 patients under FDA Emergency Use Authorization (EUA).
"ExThera’s partnership with Asahi Kasei Medical is an important milestone in our collaborative ongoing fight against life threatening pathogens. We are pleased to partner with the Japanese market leader in extracorporeal therapeutics who is motivated to commercialize Seraph 100 and join our global pursuit of saving lives of those suffering from severe sepsis/septic shock," said Robert Ward, ExThera Medical Chairman and CEO.
Chitty et al, A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report, (2021)
Schmidt et al, Interim-analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry, NDT, 2021; gfab347
About Asahi Kasei and Asahi Kasei Medical
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 40,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Asahi Kasei Medial is a core operating company in the Health Care sector that develops and markets devices and systems for dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics.
For more information, visit www.asahi-kasei.com and www.asahi-kasei.co.jp/medical/en/.
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address infections caused by battlefield wounds or pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, participation in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100® is CE marked and commercially available in the EU and has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.
For more information visit the company’s website at www.extheramedical.com.
As a patient's blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby removed from the bloodstream. Seraph targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis. The ‘antithrombogenic’ heparin media can be combined with other ExThera-proprietary media to tailor the capability of future Seraph products for the treatment of specific diseases, or to further broaden Seraph’s capability.
For more news stories on the Seraph 100 click here.
All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005589/en/
ExThera Medical Corporation Corporate Communications Lauren Popiel Phone: +1-925-839-2060 Email: media@extheramedical.com
Asahi Kasei Corp. Corporate Communications Phone: +81-(0)3-6699-3008 Fax: +81-(0)3-6699-3187
AbbVie's immunology drug Skyrizi could soon be approved in the European Union to treat patients with Crohn's disease.
Amy Sussman/Invision/APTim Bergling was about to enter his second year of high school when he took his first hit of a friend’s joint. He immediately hated it. The teenager–who in a few years’ time would become internationally known as the EDM DJ Avicii–suddenly felt his throat turn scratchy and dry from the intake of marijuana, as his heart started pounding and paranoia crept in.The sensation eventually passed, but when Avicii returned home to Stockholm after his summer trip to the French Rivier
There were 592 new, confirmed cases of COVID-19 in Monroe County for the week of December 16-22.
This company's market value plunged by around $8 billion in 2021, leading contrarian investors to suspect a bargain opportunity.
Not even the government is sure whether you'll end up paying more or paying less.
The U.S. Centers for Disease Control and Prevention is investigating more cruise ships due to new cases of COVID-19 as the omicron variant drives extremely high infection levels in the industry hub of Florida. The CDC said 88 vessels are now either under investigation or observation, but it did not specify how many COVID-19 cases have been reported. Four other vessels are also being monitored by the CDC as well.
Opinion: A local ER physician answers questions for the Register about antiviral pills, home tests, and who's occupying hospital beds.
WASHINGTON - Fareha Ahmed had been cautious since the beginning of the pandemic. She had eaten in restaurants only three times. She and her husband were vaccinated and boosted, and their 7-year-old got vaccinated in November as soon as he was eligible. In mid-December, Ahmed, 39, who lives in Washington, D.C., met a former colleague for an outdoor lunch. A few days later, the family attended an indoor gathering for the first time with other families, to bake Christmas cookies. Then covid caught
Photo Illustration by The Daily Beast/GettyThe U.S. Food and Drug Administration has granted emergency-use authorization to two prescription COVID pills that patients with mild-to-moderate infections can take at home and that, to varying degrees, can prevent the worst outcomes. Serious illness. Hospitalization. Death.Doctors were counting on the new pills, from New Jersey pharma Merck and Pfizer in New York, to help keep people out of hospitals as the Delta and Omicron lineages of the SARS-CoV-2
via YouTubeAn Italian anti-vaxxer and COVID-denier who sparked outrage after declaring himself a “plague spreader” and boasting about how he walked around sick and maskless in a supermarket has died of COVID-19, according to local media reports.Maurizio Buratti, also known as Mauro from Mantua, died in a Verona hospital Monday, just a few weeks after being hospitalized. He was 61.Buratti’s condition took a turn for the worse, perhaps unsurprisingly, after he called in to the Zanzara radio progra
The pandemic may have brought these companies to prominence, but there's much more to the story.
The No Surprises Act, which is putting an end to surprise medical bills from out-of-network providers, is scheduled to go into effect on Jan. 1, 2022. According to federal estimates, it will apply to...
What happens when you transition from a plant-based diet to an omnivorous one? We asked a dietitian to find out.
Recall alert: Check your diabetes medication
The Centers for Disease Control and Prevention made significant revisions to its omicron new-case estimates. In new data released Tuesday, the federal agency said new cases of omicron accounted for just 22.5% of new cases for the week ending Dec. 18, not 73% as originally estimated. For the week ending Dec. 25, omicron accounted for 58.6% of new coronavirus cases compared to 41.1% of delta, the CDC said.
A new paper by researchers at the University of Southern California and RAND Corporation sheds light on other advantages of being vaccinated.
France's government is forging ahead with efforts to increase pressure on unvaccinated people to get coronavirus shots, as the country reported 208,000 new COVID-19 cases Wednesday — a record fueled by the omicron variant.
With the omicron COVID variant proving more transmissible than any other, there's a very good chance you'll catch it, no matter how careful you are. To keep you safe, Dr. Tatiana Prowell, an Associate Professor of Oncology at Johns Hopkins School of Medicine, who serves people with COVID-19, tweeted a viral thread to lay out exactly what you should do the minute you or someone you know has symptoms (and she described the symptoms, too). Read on for the exact steps—and to ensure your health and t
A UAB investigated covid treatment from Mereo BioPharma Group shows positive results in early clinical trial.
If you're eligible for a COVID-19 vaccine booster shot, you don't have to stick with the same company that manufactured your primary dose(s).